Iben S. Darfelt

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

F. Kapadia, J. Divatia, S. Myatra, 2022, Intensive Care Medicine.

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.

F. Kapadia, V. Jha, J. Divatia, 2021, JAMA.

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial

F. Kapadia, V. Jha, J. Divatia, 2021, medRxiv.

Thromboembolic and bleeding events in ICU patients with COVID‐19: A nationwide, observational study

A. S. Andreasen, L. Poulsen, A. Perner, 2022, Acta anaesthesiologica Scandinavica.

Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia – a post hoc evaluation of the COVID STEROID 2 trial

J. Divatia, S. Myatra, A. S. Andreasen, 2023, The Lancet regional health. Southeast Asia.